However, combining the αvβ8 antibody, which inhibits TGF-β activation, resulted in significant tumor inhibition, suggesting that simultaneous blockade of TGF-β signaling and PD-1/PD-L1 can overcome the immunosuppressive barriers of the immune-excluded tumor microenvironment. Here, CD274 is linked to neoplasm.